Literature DB >> 28134920

Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

Y Le Bris1, T Guillaume2, A Ménard1, M Illiaquer3, J Martin4, S Malard5, A Duquesne5, P Peterlin2, C Debord1, N Robillard1, M Eveillard1, S Wuillème1, J Delaunay2, M Mohty6, A Garnier2, P Moreau2, M C Béné1, P Chevallier2.   

Abstract

Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, associated with indolent clinical courses and favorable outcomes. Here, we considered 85 recipients of UCB allo-HSCT to more broadly define the impact of lymphocytosis, not limited to LGL. Sustained lymphocytosis was observed in 21 (25%) patients at a median onset of 12.6 months and with a median duration of 12 months. Immunophenotypic analysis showed predominantly CD8+ T and/or polyclonal B-cell expansions. Three patients only had monoclonal T-cell expansion. CMV reactivation was significantly more frequent in the group of patients with lymphocytosis (76% vs 28%, P=0.0001), but was not associated with survival. Conversely, 2-year disease-free survival and overall survival were significantly higher for lymphocytosis patients (85% vs 55%, P=0.01 and 85% vs 63%, P=0.03, respectively). In conclusion, expansion of T or B lymphocytes after UCB allo-HSCT in adults is not a rare event. Although occurring relatively late after transplant, this feature is predictive of a better outcome for the patients.

Entities:  

Mesh:

Year:  2017        PMID: 28134920     DOI: 10.1038/bmt.2016.364

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction.

Authors:  Mehdi Alizadeh; Marc Bernard; Bruno Danic; Charly Dauriac; Brigitte Birebent; Christine Lapart; Thierry Lamy; Pierre-Yves Le Prisé; Alain Beauplet; Dominique Bories; Gilbert Semana; Erwann Quelvennec
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

2.  Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.

Authors:  Roberto Bellucci; Edwin P Alyea; Edie Weller; Antoinette Chillemi; Ephraim Hochberg; Catherine J Wu; Christine Canning; Robert Schlossman; Robert J Soiffer; Kenneth C Anderson; Jerome Ritz
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

Authors:  Margaret L Green; Wendy M Leisenring; Hu Xie; Roland B Walter; Marco Mielcarek; Brenda M Sandmaier; Stanley R Riddell; Michael Boeckh
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

4.  CMV-infected allogeneic endothelial cells initiate responder and bystander donor HLA class I release via the metalloproteinase cleavage pathway.

Authors:  Lynn D Haynes; W James Waldman; Yuri Bushkin; Robert B Love; William J Burlingham
Journal:  Hum Immunol       Date:  2005-03       Impact factor: 2.850

5.  Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection.

Authors:  B Lönnqvist; O Ringdèn; P Ljungman; B Wahren; G Gahrton
Journal:  Br J Haematol       Date:  1986-08       Impact factor: 6.998

6.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.

Authors:  Ahmet H Elmaagacli; Nina K Steckel; Michael Koldehoff; Yael Hegerfeldt; Rudolf Trenschel; Markus Ditschkowski; Sandra Christoph; Tanja Gromke; Lambros Kordelas; Hellmut D Ottinger; Rudolf S Ross; Peter A Horn; Susanne Schnittger; Dietrich W Beelen
Journal:  Blood       Date:  2011-05-03       Impact factor: 22.113

7.  Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

Authors:  Bernard Rio; Sylvie Chevret; Stéphane Vigouroux; Patrice Chevallier; Sabine Fürst; Anne Sirvent; Jacques-Olivier Bay; Gérard Socié; Patrice Ceballos; Anne Huynh; Jérôme Cornillon; Sylvie Françoise; Faezeh Legrand; Ibrahim Yakoub-Agha; Gérard Michel; Natacha Maillard; Geneviève Margueritte; Sébastien Maury; Madalina Uzunov; Claude Eric Bulabois; Mauricette Michallet; Laurence Clement; Charles Dauriac; Karin Bilger; Eliane Gluckman; Annalisa Ruggeri; Agnès Buzyn; Stéphanie Nguyen; Tabassome Simon; Nöel Milpied; Vanderson Rocha
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-18       Impact factor: 5.742

8.  Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.

Authors:  Carolyn E Behrendt; Joseph Rosenthal; Ellen Bolotin; Ryotaro Nakamura; John Zaia; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

9.  CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.

Authors:  S Ito; P Pophali; Wu CO; E K Koklanaris; J Superata; G A Fahle; R Childs; M Battiwalla; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2013-04-08       Impact factor: 5.483

10.  Factors associated with cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation: human leukocyte antigens might be among the risk factors.

Authors:  Kadir Acar; Sahika Zeynep Akı; Zübeyde Nur Ozkurt; Gülendam Bozdayı; Seyyal Rota; Gülsan Türköz Sucak
Journal:  Turk J Haematol       Date:  2014-09-05       Impact factor: 1.831

View more
  2 in total

1.  [Clinical features and risk factors analyses of patients with T cell large granular lymphocytosis following allo-HSCT].

Authors:  F Zhao; Y Y Shi; G X Zhang; W H Zhai; A M Pang; Q L Ma; R L Zhang; J L Wei; Y Huang; D L Yang; Y He; E L Jiang; S Z Feng; M Z Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

Review 2.  Persistent Large Granular Lymphocyte Clonal Expansions: "The Root of Many Evils"-And of Some Goodness.

Authors:  Carlos Bravo-Pérez; Salvador Carrillo-Tornel; Esmeralda García-Torralba; Andrés Jerez
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.